Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tocris to supply gefitinib to cancer researchers

This article was originally published in Scrip

Executive Summary

Tocris Bioscience, a UK-based pharmaceutical supplier, has signed an exclusive deal with AstraZenecato supply the lung cancer drug gefitinib (also marketed as Iressa and Geffy) to preclinical researchers exploring cancer mechanisms. This will enable scientists to buy the fully licensed, non-formulated drug as an off-the-shelf product for use in biological research. Gefitinib has been licensed to Tocris for use as a preclinical research compound only and AstraZeneca has imposed conditions to ensure that it is not used in human studies. Last month gefitinib showed a benefit in progression-free survival over carboplatin plus paclitaxel in the first line treatment of selected non-small cell lung cancer patients (ScripOnline, August 8th, 2008).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel